our Thanks us joining and to achieved you the our half Will. today. programs. treatment we new and third of on We into of Throughout current during the morning candidates introduced product also which and targets. Good continue indications candidate thank advancing quarter, development and cancer, increases pancreatic we BPXXXX important strides accomplishments first druggable for drug build clinical of third expanded the our for everyone research range our the made the year
their in the high enables therapeutics pipeline technology technology that DNAbilize our nanoparticle and need unmet nucleic we a development delivery. with to developing platform growth proprietary of acid look DNAbilize diseases of is Our continues to RNAi for to in show come. results facilitates and treatments antisense forward the Recall encouraging quarters
Most allowing lipid cells our the drug be to to with evidence bilayer the cell. uptake antisense importantly, the diseased incorporate delivery Our to there has form no technology similar associated of high the been the cellular toxicity delivered technology. into and within with membrane, structures therefore
leukemia for Let’s acute the of start program clinical Phase the myeloid treatment or overview the AML. an of X call with
We the providing and progress knowing before in study continue steady of the forward year. end look to update to interim the make an
is As standard in untreated low-intensity or patients this prexigebersen of a high-intensity not in elected for single who eligible chemotherapy cytarabine, is trial previously a study have AML reminder regimens regimen. The a combination who otherwise or achieve or low-dose design with are LDAC, open with and multi-center arm, efficacy of in trial label, remission, combination two-stage the pharmacokinetics, complete recovery. historical complete and LDAC, recovery The rates of who is endpoint safety with with alone. compared the hematologic to assess incomplete remission for documented study pharmacodynamics, incomplete profile, response LDAC platelet to primary patients including prexigebersen a
tests. Secondary design survival, laboratory interim evaluable. endpoints analysis time performed of full are assess clinical events duration findings, as of evaluated efficacy vital evaluable and XX with examination includes signs overall after safety including and the approximately XX prexigebersen, response, adverse response, physical and patients to by trial patients will The an
standard efficiency in preclinical important program oncology studied shown frontline our have are an show StatX protein. development to small indications. In in to sample. the to interim is that was for the such profile targets safety show expand this clean we and a signal This efficacy pancreatic analysis platform models will drug this of demonstrating previous selected it technology not powered Outside study noting BPXXXX treatment penetrate to tumors successfully being and model, hopeful we third enhance we continue early our tumor AML month a candidate treatments. of BPXXXX patient-derived addition our that a the the DNAbilize cancer. It other therapeutic pancreatic for currently a to patient
combination currently our tackling benefit both has with that demonstrated note in Prexigebersen preclinical On we with Earlier X ovarian also preclinical results initiate we the prexigebersen GrbX recent clinical proprietary begin and to for is treatments. a Phase several solid for and our studies. in penetration We monotherapy Phase tumor as promising cancers the excited in tumor a ovarian trial treatment blood recently the plan of standard candidate platform. also tumors this tumors. prexigebersen, are frontline demonstrated We the in of protein, month showed types which technology announce development targets prexigebersen. lead XXXX including to solid that X in
in and highly CML before a portion X of results on of are clinical and prexigebersen’s end by enrollments track to the Phase preclinical trial encouraged remain the in We begin safety XXXX.
second the addition BclX BPXXXX, activity our drug reported results strong encouraging protein, candidate model. to program, November, preclinical our and recently announced in in In anti-nonHodgkin’s lines an demonstrated cell we BPXXXX. for we that, animal In prexigebersen targets which lymphoma
initiate X in expect XXXX. trial a to lymphoma We Phase in
to allowance continue platforms develop overview which a assets may to their I’ll we in build intellectual property turn expand to strategic exciting growing protects autoimmune technology to Finally, further as from capabilities. ability barriers correction. the of technology our would With our areas infectious and portfolio, our now and In July, received our for notice estate to we our Price fullest U.S. the Trademark key of for diseases. a and believe that, We variety United protection DNAbilize. a provides of of will that prove new of outcomes application will us over call to patients the treatment composition an patent these technology provide our and a strong financials. Patent competitors approach DNAbilize DNAbilize of and outside Anthony of for well in States as for the patent The Office improve allow broad patent matter to for be and innovative monetize our cancers brief
